Royalty Pharma Plc (RPRX) — Capital Reinvestment Ratio

Latest as of September 2025: 0.00x

Royalty Pharma Plc (RPRX) has a Capital Reinvestment Ratio of 0.00x as of September 2025, meaning it reinvests 0% of its operating cash flow ($702.62 Million) in capital expenditures ($1.11 Million). See RPRX net asset quality score to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.00x
Capex / Operating Cash Flow

Operating Cash Flow

$702.62 Million
USD

Capital Expenditures

$1.11 Million
USD

Data as of

Sep 2025
Most recent filing

Royalty Pharma Plc Capital Reinvestment Ratio (2002–2023)

This chart tracks Royalty Pharma Plc's Capital Reinvestment Ratio across 8 annual periods. Check RPRX cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Royalty Pharma Plc (2002–2023)

Year-by-year Capital Reinvestment Ratio for Royalty Pharma Plc from 2002 to 2023. For live market cap and broader valuation context, see Royalty Pharma Plc (RPRX) total market value.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2023 0.71x $2.99 Billion $2.12 Billion ▼ -25.6%
2022 0.95x $2.14 Billion $2.04 Billion ▲ +367160.5%
2021 0.00x $2.02 Billion $523.00K ▼ -100.0%
2020 1.08x $2.03 Billion $2.20 Billion ▲ +4.6%
2019 1.03x $1.67 Billion $1.72 Billion ▲ +519.7%
2018 0.17x $1.62 Billion $269.59 Million ▼ -89.7%
2017 1.62x $1.42 Billion $2.29 Billion ▲ +27735.6%
2002 0.01x $8.45 Million $49.00K
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow